Back to top
more

OvaScience Inc. (OVAS)

(Delayed Data from NSDQ)

$0.69 USD

0.69
103,833

0.00 (0.00%)

Updated Dec 7, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Tempest Therapeutics, Inc. [OVAS]

Reports for Purchase

Showing records 1 - 20 ( 92 total )

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OVAS

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

07/22/2018

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/16/2018

Daily Note

Pages: 3

Refocus on Science Should Aid in the Long Term; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/06/2017

Company Report

Pages: 6

We Expect the Path Ahead to Be Science Driven

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/04/2017

Company Report

Pages: 6

2Q17 Update: Continued Focus on OvaPrime and OvaTure Lays Groundwork for Catalysts Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/24/2017

Company Report

Pages: 4

We are dropping coverage of OVAS shares to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/24/2017

Daily Note

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/12/2017

Company Report

Pages: 5

Initial Clinical Readout From OvaPrime by Year-End Is Next Catalyst

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/03/2017

Company Report

Pages: 5

4Q16 Update: Value of the Road More Travelled

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

12/19/2016

Company Report

Pages: 4

We are transferring coverage of OVAS to Sa''ar Yaniv from Scott Henry as part of a realignment process for our Healthcare coverage universe. Shares of OVAS were previously Under Review, with no estimates or price target

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/04/2016

Company Report

Pages: 7

Our Thoughts on the Next Augment Study and 3Q Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

10/07/2016

Company Report

Pages: 4

Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/09/2016

Company Report

Pages: 7

A Fresh Start Underway

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

02/16/2016

Company Report

Pages: 8

You Only Launch Twice; We Maintain Our Buy Rating and Lower PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/14/2015

Industry Report

Pages: 7

Ideas List -- September 2015 Performance

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/30/2015

Company Report

Pages: 11

Procedure Update Questions the "When" - "If" Story Seems Intact - IVF Clinic Consolidation Delays UAE Ramp - Lowering PT from $46 to $15 - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

09/08/2015

Company Report

Pages: 11

Sliding OVAS Off the Wedbush Best Ideas List - Less Optimism for Near Term Positive Catalysts - 2016 Consensus Not Helping Matters - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/27/2015

Daily Note

Pages: 11

Egg splitting Publication Slightly Better than Our Thinking - No New Volume or Sales Visibility - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Tempest Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

08/27/2015

Daily Note

Pages: 11

Egg splitting Publication Slightly Better than Our Thinking - No New Volume or Sales Visibility - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party
// eof